恩度联合顺铂胸腔内注射治疗非小细胞肺癌恶性胸腔积液临床观察

摘要

Objective To observe the efficacy and safety of intrapleural injection of endostar with DDP in treatment of non-small cell lung cancer with malignant pleural effusion. Methods 8 cases of lung cancer with malignant pleura! effusion were injected with en-dostar with DDP, which can be duplicated in the sight of the volume of absorption of pleural effusion a week later. The quality of life (QOL) and clinical efficacy were evaluated after the injection. Results The effective rate was 87.5% , QOL improvement rate was 87. 5%. The toxicity was relatively small. Conclusion Intrapleural injection of endostar with DDP in treatment of non-small cell lung cancer with malignant pleural effusion is safe and practicable, and has better recent efficacy. It is worthy of clinically adoption and generalization.%目的 观察恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的临床疗效和安全性.方法 8例肺癌恶性胸腔积液患者,予顺铂、恩度联合注入,视胸水吸收情况一周后可以重复.使用后评价临床疗效、生活质量并观察毒副反应.结果 8例患者治疗胸水有效率为87.5％,生活质量改善率为87.5％.毒副反应较少.结论 恩度联合顺铂治疗非小细胞肺癌恶性胸腔积液是一种安全、可行的治疗手段,有较好的近期疗效,值得临床推广应用.